FLT3 and acute myeloid leukemia: Additionally, screening of the AML/LPC immunopeptidomes for peptides derived from common AML-specific mutations (e.g. FLT3, NPM1, IDH2, DNMT3A) enabled the identification of naturally presented neoepitopes of NPM1 and IDH2.